Analysis of Overall Survival in Patients With Nonmetastatic Castration-Resistant Prostate Cancer Treated With Vaccine, Nilutamide, and Combination Therapy

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-07-5048
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Predictive Factors of Response and Overall Survival in Patients With Castration-Resistant Metastatic Prostate Cancer Undergoing177Lu-Psma Therapy

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2018English

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Yearbook of Paediatric Endocrinology
2019English

Pcn346 - Disease Specific Cost Analysis of the Nonmetastatic Castration-Resistant Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer Health States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Survival in Men With Nonmetastatic Prostate Cancer Treated With Hormone Therapy: A Quantitative Systematic Review

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2007English

Prostate-Specific Antigen Decline After 4 Weeks of Treatment With Abiraterone Acetate and Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer

European Urology
Urology
2016English

Treatment Sequences, Patient Characteristics, and Overall Survival of Patients With Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer in the Community Setting

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Circulating Tumor Cell Analysis in Patients With Progressive Castration-Resistant Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2007English

Pcn336 - Treatment of Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With Docetaxel in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Safety and Preliminary Efficacy Analysis of the mTOR Inhibitor Ridaforolimus in Patients With Taxane-Treated, Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer
OncologyUrology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy